{"podcast":{"title":"Business Of Biotech","slug":"business-of-biotech-123501","podcast_index_feed_id":123501,"rss_url":"https://rss.buzzsprout.com/1011661.rss","website_url":"https://www.bioprocessonline.com/solution/the-business-of-biotech-podcast","image_url":"https://storage.buzzsprout.com/35u0bccu9j9xpr9zrrjias54otax?.jpg","author":"Ben Comer","episode_count":324,"summary":"The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.","last_synced_at":"2026-09-14T18:21:24.973502+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501"},"episode":{"title":"Targeting Tau in Alzheimer's Disease With Voyager Therapeutics' Al Sandrock, M.D., Ph.D.","slug":"targeting-tau-in-alzheimer-s-disease-with-voyager-therapeutics-al-sandrock-m-d-ph-d","published_at":"2026-06-29T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/targeting-tau-in-alzheimer-s-disease-with-voyager-therapeutics-al-sandrock-m-d-ph-d","show_page_url":"https://stenobird.com/podcast/business-of-biotech-123501","url":"https://www.buzzsprout.com/1011661/episodes/19372075-targeting-tau-in-alzheimer-s-disease-with-voyager-therapeutics-al-sandrock-m-d-ph-d.mp3","audio_url":"https://www.buzzsprout.com/1011661/episodes/19372075-targeting-tau-in-alzheimer-s-disease-with-voyager-therapeutics-al-sandrock-m-d-ph-d.mp3","summary":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Al Sandrock, M.D., Ph.D., President and CEO at Voyager Therapeutics, talks about why tau is becoming a central target in Alzheimer’s drug development and how gene therapy delivery across the blood-brain barrier could change what treatment looks like at scale. Sandrock shares his current thinking on the amyloid vs. beta debate (it's likely both) in Alzheimer's disease treatment, the role ...","meta_description":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Al Sandrock, M.D., Ph.D., President and CEO at V…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2914,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/targeting-tau-in-alzheimer-s-disease-with-voyager-therapeutics-al-sandrock-m-d-ph-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/targeting-tau-in-alzheimer-s-disease-with-voyager-therapeutics-al-sandrock-m-d-ph-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}